Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 1,816.7% in April

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 34,500 shares, a growth of 1,816.7% from the March 31st total of 1,800 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 0.0 days.

Palisade Bio Trading Down 2.9 %

Shares of Palisade Bio stock traded down $0.18 during trading on Friday, reaching $6.05. The company’s stock had a trading volume of 266,852 shares, compared to its average volume of 2,816,004. The stock has a 50-day moving average price of $5.72 and a two-hundred day moving average price of $7.51. Palisade Bio has a one year low of $3.82 and a one year high of $36.60. The stock has a market capitalization of $5.15 million, a P/E ratio of -0.22 and a beta of 1.33.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($3.75) earnings per share for the quarter. As a group, sell-side analysts anticipate that Palisade Bio will post -12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “buy” rating and set a $22.50 price target on shares of Palisade Bio in a research note on Tuesday, April 16th.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.